PCI Evolution in Infiltrative Diseases

Infiltrative diseases (ID) consist of a heterogeneous series of genetic conditions that cause infiltration and extracellular deposits which alter the diverse systems and organs affected.   

ATC en enfermedades infiltrativas

Amyloidosis, sarcoidosis and hemochromatosis affect the heart, altering the myocardium and the conduction system. 

PCI is often used at present to treat heart disease, and some of these patients present ID. Different analysis suggest that PCI might evolve differently vs. patients with no ID; however, it has not yet been thoroughly looked into. 

There was a retrospective analysis, from January 2016 to December 2020, including 2,360,860 patients; 7,855 (0.77%) with ID (amyloidosis 990, sarcoidosis 5,260 and hemochromatosis 1,625).

Read also: TAVR in Low Risk Patients: 10 Year Evolution.

Primary end point was the post-PCI combination of inhospital death, stroke and major bleeding. 

Patients with amyloidosis were older and had more comorbidities vs. sarcoidosis and hemochromatosis patients. 

Primary end point resulted more frequent in amyloidosis patients (1.6% vs. 1.1% vs. 1.18%, OR 1.6; CI del 95%, 1.1-2.44; P= .02 for amyloidosis, sarcoidosis and hemochromatosis, respectively); they also showed higher mortality (1.9% vs. 1.09% vs. 0.72%, P<0.05), and stroke (4% vs. 0% vs. 2.28%, P<0.05), but there were no significant differences in major bleeding (2.2% vs. 0.96% vs. 1.03%, p>0.05).

Read also: Sub-Analysis of the REVIVED-BCIS2: Myocardial Viability Changes Prognosis in Ischemic Cardiomyopathy Revascularization?

The cost of hospitalization and hospital stay was higher in patients with amyloidosis. 

Conclusion

Amyloidosis was associated with worse evolution after PCI, including higher inhospital mortality, intra and post procedural stroke, and socioeconomic cost. We highlight the need for a multidisciplinary approach for better assessment and further research, to better guide the screening and management strategy of these patients. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Clinical Outcomes of Percutaneous Coronary Intervention in Amyloidosis, Sarcoidosis, and Hemochromatosis.

Reference: Bilal Hussain, et al. JSCAIhttps://doi.org/10.1016/j.jscai.2023.101267. Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

Drug-Eluting Stents in Peripheral Arterial Disease: When Should They Be Used?

Peripheral drug-eluting stents have transformed the treatment of peripheral arterial disease by reducing restenosis rates and the need for repeat interventions. However, the emergence...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...